Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.77 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.73 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.73 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | CDC42 | P60953 | 1/20 | 0.73 |
| ▸ | RAC1 | P63000 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.60 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL505819 | 1.00 | TDP1 (0.77) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL29508603 | 1.00 | TDP1 (0.77) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL8754690 | 1.00 | TDP1 (0.77) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL29403959 | 1.00 | TDP1 (0.77) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL505811 | 1.00 | TDP1 (0.77) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL11015007 | 0.97 | TDP1 (0.73) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL14364989 | 0.91 | TDP1 (0.65) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL12744118 | 0.91 | TDP1 (0.69) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL9551659 | 0.90 | TDP1 (0.77) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 | |
| SCHEMBL12744138 | 0.89 | PTGS2 (0.63) | TDP1L3MBTL1PTGS2AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102388014-A | Synthesis method of chiral alpha-aryl propionic acid derivative | DSM IP ASSETS BV | 2012-03-21 | — | — | CN | disclosed |
| US-20120029226-A1 | METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2012-02-02 | — | — | US | disclosed |
| US-5587318-A | FROM RACEMIC MIXTURES OF THE CORRESPONDING ESTER BY ENANTIOSPECIFIC HYDROLYSIS USING LIPASE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1996-12-24 | — | — | US | disclosed |
| US-5322791-A | Enantiospecific hydrolysis | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1994-06-21 | — | — | US | disclosed |
| EP-0227078-A1 | Process for preparing (S)-alpha-methylarylacetic acids | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1987-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029226-A1 | METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES | GRIA1, GRIA3, GRIA2 | TDP1 4606/4885L3MBTL1 4261/4885PTGS2 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.